Pikralidasp. z o.o.
Research and experimental development in natural sciences and engineering
Overview
Pikralida is a biotechnology company combining research and development (R&D) with CRO services for the pharmaceutical sector, and carries out projects at the clinical stage. It develops therapies for unmet medical needs, including PKL-021, an active inhibitor of enzymes in the metalloproteinase group. Its Poznan laboratory develops medicinal product formulations, while its Warsaw laboratory develops manufacturing processes for active substances.
- ul. Rydygiera 8 bud. 13, 01-793 Warszawa
Financials
Revenue history (in k)
Financial insight
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.
Filing timeliness
Financial statements were filed on time, on average 40 days early.
- 202513/07/2026
- 202407/07/2025
- 202325/06/2024
- 202211/07/2023
- 202130/06/2022
- 202006/04/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Industry
Offer
- Chemical synthesis
- Drug formulation development
- Pharmaceutical analysis
- Analytical method validation
- CRO services
Website technology
- Website
- WordPress
- Elementor
Public procurement
1 tender recorded as contractor, with a total value of $139,038.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Apr 7, 2023 | “Analytical certification, stability testing of urolithin A and development of a prototype medicinal product in the form of a cream containing urolithin A” | $139K$139,038 | Warszawski Uniwersytet Medyczny |
Trademarks
Pikralida holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2022.
| Mark | Protected until | |
|---|---|---|
| Pikralida | Feb 21, 2032 |
Authorized Representatives
Manner of representation
In the case of a multi-member management board, the company is represented by the President of the Management Board of the company independently, or by two members of the management board of the company jointly, or by one member of the management board acting jointly with a commercial proxy.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 232 | $3,133.44 | 11.4795% | |
Anna Barbara Krauseage 50 | 480 | $6,482.98 | 23.7506% |
Joanna Karolina Lipnerage 42 | 480 | $6,482.98 | 23.7506% |
Stanisław Wiesław Pikulage 68 | 488 | $6,591.03 | 24.1465% |
Others | 341 | $4,605.62 | 16.8728% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2019-03-27.
07 1600 1462 1738 2477 3000 0019- 34 1600 1462 1738 2477 3000 0018
- 61 1600 1462 1738 2477 3000 0017
Debt
No entries in the National Debtors Register (KRZ).
Public aid
27 public aid cases recorded, with a total value of $12,576,939.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 27, 2026 | Aid for SMEs for innovation support | –– | Prezes Banku Gospodarstwa Krajowego | |
| Dec 22, 2025 | Aid for research and development projects: industrial research | –– | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Dec 22, 2025 | Aid for research and development projects: experimental development | –– | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-04-01 | Development of an intravenous formulation of an innovative neuroprotective drug for patients after stroke | $5.5M$5,534,687 | European Funds for a Modern Economy | |
| 2021-01-01 | Use of a matrix metalloproteinase inhibitor to develop an innovative therapeutic method for preventing the development of post-traumatic and post-stroke epilepsy | $4.1M$4,075,264 | Operational Programme Smart Growth | |
| 2019-10-31 | Establishment of a supergeneric drug laboratory. | $260.8K$260,815 | Wielkopolska Regional Operational Programme for 2014 – 2020 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| MolecureS.A. | $1,889,300.60 | molecure.com | ||
| Pure Clinicalsp. z o.o. | $1,676,907.27 | pureclinical.eu | ||
| BiokineticaS.A. | $1,292,838.89 | biokinetica.com | ||
| COS LabP.S.A. | $1,275,339.79 | coslab.pl | ||
| Scope FluidicsS.A. | $1,264,188.85 | scopefluidics.com | ||
| Ecoverseasp. z o.o. | $891,022.45 | coslab.pl | ||
| MPR Labssp. z o.o. | $833,714.20 | mpr-labs.com | ||
| Analytical R & Dsp. z o.o. | $715,583.52 | analytical.pl | ||
| Polbiotech Laboratoriumsp. z o.o. | $645,943.81 | polbiotech.pl | ||
| BioceltixS.A. | $616,315.97 | bioceltix.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-10-12 | Share capital increase (82,000.00 PLN → 101,050.00 PLN) | |
| 2023-05-26 | Share capital increase (36,000.00 PLN → 82,000.00 PLN) | |
| 2022-01-25 | Address change (Ul. Bukowska 70/B424, 60-812, Poznań → Ul. Uniwersytetu Poznańskiego 10, 61-614, Poznań) | |
| 2020-08-21 | Share capital increase (20,000.00 PLN → 36,000.00 PLN) | |
| 2019-02-21 | Entered in the register |
FAQ
Last updated: 2026-10-12